Lo William Wing Yan Dr reported option exercise involving 36,001 derivative units of Regencell Bioscience Holdings Ltd at $0.00 for $0 on Nov 17, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed Nov 17, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
36,001Stock option (right to purchase)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
485,629Direct
Trade date
Nov 17, 2026Option exercise
Filed
Nov 17, 2026, 4:15 PM ET0-day reporting delay
Accession
0001213900-26-121409Code M · Transaction 403296
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 17, 2026Option exercise36,001$0.84$30,240.84Trade 403295
2 transaction rows in this filing. Joint filers share the same rows.

RGC price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
RGC · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago 0%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: The exercise price has given effect to the share split(s) of the Issuer since the date of grant of the option.